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OBJECTIVES: Catheter ablation is increasingly used to maintain sinus rhythm in 
atrial ﬁbrillation (AF) patients unresponsive to antiarrhythmic drugs (AADs). We 
compared medical costs in Medicare-aged AF patients following successful vs unsuc-
cessful ablation. METHODS: In this retrospective study, AF pts with 1) an index 
ablation; 2) ≥12 months’ medical/pharmacy coverage pre- and post-index; 3) ≥2 AF 
inpatient/outpatient visits within 6 months and AAD treatment within 12 months of 
index ablation were identiﬁed from the MarketScan® Medicare database (January 
2002-June 2007). Ablation success was deﬁned as absence of AAD treatment 6–12 
months post ablation. RESULTS: A total of 135 AF patients (67% men, mean 73 yrs) 
were included; ablation was successful in 69 and failed in 66 patients. Most patients 
(97% with successful vs 94% with failed ablation) underwent only 1 ablation proce-
dure during the 12-month study. After successful ablation, patients discontinued AAD 
in (mean) 54 days. Use of rate-control and anticoagulant drugs declined after success-
ful ablation (67% vs. 87% and 64% vs. 86% patients, respectively), but remained 
largely undiminished after failed ablation (70% vs. 74% and 82% vs. 88% patients, 
respectively). Mean (median) per-patient costs per ablation were $13,655 ($11,795) 
for successful vs. $17,294 ($11,778) for failed ablation. Other AF-related costs over 
1 yr post index ablation were $2394 ($7677) for successful vs. $2703 ($4478) for 
failed ablation patients. Overall annual per-patient costs were lower in patients with 
successful (mean $16,049; median $17,135) vs. failed ($19,997; $26,635) ablation (P 
= 0.07). CONCLUSIONS: Ablation failed in half of ‘real-world’ Medicare-aged AF 
patients, and few underwent repeat ablation. Overall costs were higher for failed vs 
successful ablation patients, possibly because of differences in AF-related issues, com-
plications, and ablation methods. Over time, this cost differential would likely increase 
if failed ablation patients underwent repeat procedures. Identiﬁcation of predictors for 
ablation success may reduce medical costs.
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OBJECTIVES: To develop a parsimonious risk-beneﬁt model to assist stakeholders in 
evaluating gene expression proﬁling (GEP) to guide use of adjuvant chemotherapy in 
early stage breast cancer compared to clinical guidelines. METHODS: A decision 
model was developed to estimate comparative beneﬁts and harms of using GEP relative 
to NCCN guidelines, including disease recurrences, adverse events, life years, and 
quality-adjusted life years (QALYs). Model structure and output were developed 
through a collaborative feedback process with stakeholders. The model’s interactive 
structure allows users to specify the GEP, adjuvant chemotherapy regimen, and prog-
nostic and predictive risk stratiﬁcation. A Markov process was utilized to estimate 
clinical outcomes, and parameter uncertainty was evaluated through one-way and 
probabilistic sensitivity analysis. The base case patient was a pre-menopausal woman 
of age 44. The prognostic and predictive properties of the GEPs were derived from 
published retrospective analyses of RCTs. Adjuvant chemotherapy regimen-speciﬁc 
utility decrements were incorporated based on trial-based adverse event rates. 
RESULTS: Preliminary analyses indicate that a GEP that provides prognostic informa-
tion only would identify 61% of women to receive adjuvant chemotherapy, while 
96% would be identiﬁed by clinical guidelines. Based on these estimates, GEP and 
clinical guidelines would prevent 29% and 34% of distant recurrences, respectively. 
These ﬁndings suggest that GEP may lead to a net harm, with 9.86 QALYs for GEP 
versus 10.08 for clinical guidelines, due to increased risk of disease recurrence, despite 
the avoidance of chemotherapy and side effects in 39% of women. Analyses of other 
risk stratiﬁcation approaches are ongoing. CONCLUSIONS: We found that use of 
GEP to guide use of adjuvant chemotherapy in early stage breast cancer could lead to 
a decrease in QALYs relative to the use of clinical guidelines if chemotherapy predic-
tive information is not available. Ongoing efforts are focused on collaboration with 
stakeholders to align model structure and output with stakeholder needs.
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OBJECTIVES: Systemic chemotherapy is a vital component of breast cancer manage-
ment. However early-onset chemotherapy-toxicities like neutropenia hinder chemo-
therapy use in breast cancer patients, especially in the elderly. Depending on the 
severity, neutropenia management requires hospitalization and aggressive systemic 
antibiotic administration, and involves reduction or discontinuation of chemotherapy. 
Primary prophylactic granulocyte-colony stimulating factors (PPG-CSF), especially 
when administered over adequate duration, help prevent neutropenia. Nevertheless, 
evidence supporting the effectiveness of PPG-CSF in the elderly is limited, and thus 
the ASCO guidelines for PPG-CSF use and speciﬁcations for duration of its use in the 
elderly are not explicit. This study analyzed the effects of PPG-CSF and adequate 
duration of PPG-CSF on the occurrence of chemotherapy-induced neutropenia hospi-
talizations in elderly breast cancer patients. METHODS: A retrospective observational 
study for patients newly diagnosed with primary breast cancer between the years 1994 
to 2002 using the SEER-Medicare data was performed. To account for the non-ran-
dom nature of the observational data a non-parametric covariate genetic matching 
technique was used to pre-process the data before performing logistic regressions to 
estimate the treatment effects. RESULTS: Administration of PPG-CSF during the ﬁrst 
course of chemotherapy reduced neutropenia hospitalizations by 15% within the ﬁrst 
three months and 16% within the ﬁrst six months of chemotherapy initiation (p < 
0.05). Hospitalizations within the ﬁrst three months of chemotherapy initiation were 
three times higher in women receiving less than ﬁve consecutive days of PPG-CSF 
compared to women receiving PPG-CSF for ﬁve of more days (p < 0.05). Hospitaliza-
tions within the ﬁrst one and six months were also considerably lower with longer 
PPG-CSF duration (≥5days) (p < 0.10). CONCLUSIONS: PPG-CSF use is associated 
with reduction in occurrence of severe neutropenia and reduced in-patient health care 
utilization. These ﬁndings have implications for ASCO guidelines and Medicare cover-
age policies for PPG-CSF administration and duration of administration in elderly 
breast cancer patients.
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OBJECTIVES: Amnestic Mild Cognitive Impairment (AMCI) patients with Apolipo-
protein e4 alleles (APOEe4), a type of genetic mutation, have higher rates of progres-
sion to Alzheimer Disease (AD) than patients without this genetic mutation. Some 
studies suggest that early diagnoses and treatment in APOE e4 carriers will delay their 
progression to AD.Objective is to evaluate the cost-effectiveness of APOEe4 testing in 
combination with preventive Donepezil treatment in AMCI patients in Canada. 
METHODS: We performed a cost-effectiveness analysis using a Markov model based 
on a formal literature review. The base case was assumed to be a 70-year-old AMCI 
individual with problems in the memory domain. The model used a societal perspec-
tive and a time horizon of 30 years. Two strategies were evaluated: genetic testing and 
preventive Donepezil treatment for APOEe4 gene carriers vs. no testing (the current 
standard of care in Canada). Outcome measures were quality-adjusted life years 
(QALYs), lifetime costs, and the incremental cost-effectiveness ratio (ICER). RESULTS: 
The genetic testing and Donepezil treatment combination strategy resulted in the gain 
of 0.047 QALYs, when compared to not testing. The Incremental cost was CAD $ 
1010 with Donepezil treatment; consequently, the ICER for the base case is estimated 
to be $ 21,586. The prevalence of genetic mutations, cost of genetic test and cost of 
Alzheimer disease had a small effect on the cost-effectiveness results; however, the 
ICER is sensitive to AMCI utility, rate of progression to AD, AMCI surveillance cost, 
efﬁcacy and cost of Donepezil preventive treatment. We conducted a sub-analysis by 
sex, and found that the ICER was lower for females than for males. CONCLUSIONS: 
Genetic testing in combination with preventive donepezil treatment for AMCI patients 
may be economically attractive in the current setting. Our preliminary ﬁndings are 
limited by substantial uncertainties surrounding the long-term efﬁcacy of Donepezil 
preventive treatment and the rate of progression to AD.
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Personalized medicine (PM) targets interventions to patients who are most likely to 
beneﬁt based on genetic clinical markers or genomic information. There is little 
research on the translation of genomics into clinical practice and health policy; this 
lack of evidence on the use, effectiveness and efﬁciency of targeted technologies is a 
key challenge to their appropriate adoption and utilization. Our conceptual approach 
to translation of PM research into practice incorporates utilization, patient and pro-
vider preferences, and health economic evaluation in breast (BC) and colorectal cancer 
(CRC). We are documenting testing and treatment patterns in Canadian and US 
patients, including which patients receive testing, with which test(s) and test sequenc-
ing when conﬁrmatory testing is performed. We are also measuring patient and pro-
vider preferences with discrete choice experiments to understand choice tradeoffs for 
testing and treatment. In the third component of our research program, we are using 
decision-analytic modeling methods to evaluate the sequelae of test-treat options. This 
analytical framework will characterise the cost-effectiveness of targeted therapy to 
estimate the value of PM interventions. Using our utilisation data, we will also 
